Category Archives: Byetta Cancer

Featured Stories

Actos, Avandia May Up Risk for Diabetic Macular Edema

A newly published study is raising concerns that patients who take Actos or Avandia may face an increased risk of developing diabetic macular edema, an eye disorder that can result in vision loss. The study, published in the Archives of Internal Medicine, found that type 2 diabetics who use thiazolidinediones, ...

Read More

Medtronic Settles Charges Over Kickbacks To Doctors

Medical device giant, Medtronic Inc., is settling charges over kickbacks to doctors. The firms just agreed to pay $23.5 million to settle claims it paid physicians kickbacks in exchange for their use of its pacemakers and defibrillators, according to a U.S. Justice Department announcement yesterday. The company was accused of seeking ...

Read More

Newly-Filed Plavix Lawsuits Claim Drug Caused Gastrointestinal Bleeds, Cerebral Hemorrhage, and TTP

The manufacturer of Plavix continues to be named in lawsuits alleging the blood thinner caused some patients to suffer from serious bleeding side effects. Most recently, the national law firm of Parker Waichman LLP filed nine Plavix bleeding lawsuits in state court in New York.

Read More

Oklahoma Woman Latest to Head to Court Over Alleged DePuy ASR Hip Implant Injuries

Lawsuits filed by alleged victims of DePuy Orthopaedics’ recalled ASR hip replacement devices continue to pile up in the multidistrict litigation currently underway in U.S. District Court, Northern District of Ohio. Most recently, a woman from Pryor, Oklahoma, filed suit alleging complications caused by a DePuy ASR hip implant ...

Read More

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

A newly published metal-on-metal hip replacement study is reporting that the majority of failures occur early, within two years of surgery. The study, published in the journal Orthopedics, is just the latest to indicate that close follow-up of metal-on-metal hip implant patients is warranted.

Read More

Johnson & Johnson’s Ethicon Division to End Sales of Gynecare Prolift, Three Other Transvaginal Mesh Devices

Johnson & Johnson’s Ethicon Inc. division revealed yesterday that it will end sales of its Gynecare Prolift device and three other transvaginal mesh products. The plan to stop selling the four products was set forth in a letter filed by the company in the Ethicon transvaginal mesh multidistrict litigation ...

Read More

J.J. Fuds, Inc. Pet Food Recalled - Listeria Contamination

J.J. Fuds, Inc. Pet Food Recalled Over Potential Listeria Contamination

J.J. Fuds, has recalled a specific lot of its J.J. Fuds Chicken Tender Chunks Pet Food over potential contamination with the dangerous, Listeria monocytogenes pathogen.

Read More

Metal-on-Metal Hip Replacement Device

Smith & Nephew’s Birmingham Metal-on-Metal Hip Replacement Device

Wright Medical Inc. took steps in to 2006 to convince the U.S. Food & Drug Administration (FDA) to reject pre-market approval of rival Smith & Nephew’s Birmingham metal-on-metal hip implant. Wright Medical, which makes two metal-on-metal hip replacement devices, the Conserve and the Lieneage device, filed a citizen petition ...

Read More

FDA Metal-On-Metal Hip Replacement Investigation Is Flawed, Researchers Say

The U.S. Food & Drug Administration’s (FDA) metal-on-metal hip replacement investigation is flawed, according to researchers.

Read More

FDA Gives 7 Companies Go Ahead To Market Generic Plavix

The U.S. Food & Drug Administration (FDA) just gave seven companies the go-ahead to market generic Plavix. Plavix is a blood thinner prescribed for the prevention of blood clots, heart attacks, and which has been linked to serious side effects such as the heart attacks and strokes it is supposed to ...

Read More

Diabetes Drug-Pancreatitis Link Supported in Another Study

mimetic-diabtes-linked-to-pancreatitis

Another study has made a connection between Type 2 diabetes drugs known as incretin mimetics and increased rates of developing pancreatitis, a known precursor to pancreatic cancer. Incretin mimetics, are GLP-1-based diabetes therapies and include Byetta and Bydureon (exenatide); Victoza … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Former Pacific Grove Mayor’s Husband Sues Over Wife’s Pancreatic Cancer, Byetta Blamed

byetta_pancreatic_cancer_lawsuit

The husband of former Pacific Grove, Washington Mayor, Sandy Koffman just filed a wrongful death civil lawsuit against two drug companies following his wife’s death from pancreatic cancer last year. His wife had been taking Type 2 diabetes drug, Byetta. … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Gum Disease Tied to Increased Diabetes Risk, May Lead to Increased Risks Tied to Some Type 2 Diabetes Drugs

gum_disease_linked_to_diseases

The links between dental disease and other diseases have been growing, for instance dental disease has been tied to increased risks for developing diabetes and heart disease; pregnancy complications; and, potentially, dementia. Type 2 diabetes is typically treated with any … Continue reading

Posted in Actos, Byetta Cancer, Pharmaceuticals |

Despite Increasing Injury Reports, Mounting Lawsuits, and Growing Data, FDA, EMA Will Not Confirm Increased Pancreatic Side Effects with Incretin Drugs

increting_drugs_side_effects

The U.S. Food and Drug Administration (FDA) agrees with the European Medicines Agency (EMA) that prevailing data concerning Type 2 diabetes medications in the class known as glucagonlike peptide-1 (GLP-1)-based diabetes therapies, do not confirm increased pancreatic side effect risks, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Many Popular Medications Contain Cancer-Causing Compounds, May Increase Cancer Risks

medications_cancer_risks

Cancer is devastating, killing about 600,000 people every year. Cancer is, in fact, the second-leading cause of death in the United States. Yet, despite consumers’ proactive measures to avoid cancer-causing products, some pharmaceuticals might contain carcinogens, ameliorating the best consumer … Continue reading

Posted in Actos, Byetta Cancer, Pharmaceuticals |

Type 2 Diabetes Medication Risks Examined in Journal Review

type2_diabetes_drugs

Incretin mimetics, a class of Type 2 diabetes drugs, are sparking debate and renewing concerns about health risks, especially to the pancreas. In fact, a piece published in the journal BMJ, states that the drugs, which include Byetta and Januvia, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Some Popular Diabetes Medications May Require Additional Review Over Potential Links to Pancreatic Cancer

Diabetes_Medications_Pancreatic_Cancer_Risk

Type 2 diabetes medications in the class known as incretin mimetics, such as Januvia and Byetta, are under increased scrutiny over recent studies discussing the drugs’ links to pancreatitis and potential increased risks to pancreatic cancer. The makers of these … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Januvia, Byetta, Other Diabetes Drugs Focus of Controversy

Januvia_Diabetes

Some popular and money making diabetes drugs are at the center of a conflict over disturbing research findings. Although Dr. Peter C. Butler declined to test its then-new diabetes medication, Januvia, he ultimately relented and, in 2008, observed that the … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Report: Diabetes Drugs Associated with Elevated Cancer Risks

A number of diabetes medications, including Byetta and Januvia, are being probed by the U.S. Food and Drug Administration (FDA) over links to pancreatic cancer. Diabetes drugs manufactured by Merck & Company Inc., AstraZeneca PLC, and other drug makers are … Continue reading

Posted in Allentown Natural Gas Explosion, Byetta Cancer, Pharmaceuticals |

Following U.S. Study, European Union Investigating Diabetes Drugs

Following news in the United States about a recent study that found that Type 2 diabetes drugs, such as Januvia and Byetta, might place patients at increased risk for pancreatic damage, including pancreatic cell growth that could lead to cancer, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

© 2005-2017 Parker Waichman LLP ®. All Rights Reserved.